Free Trial

PyroGenesis Canada (PYRGF) Competitors

PyroGenesis Canada logo
$0.21 0.00 (-0.29%)
As of 11:49 AM Eastern

PYRGF vs. BDTX, BTMD, CTOR, LFVN, KYTX, GLSI, NKTX, ALTS, ELDN, and MOLN

Should you be buying PyroGenesis Canada stock or one of its competitors? The main competitors of PyroGenesis Canada include Black Diamond Therapeutics (BDTX), biote (BTMD), Citius Oncology (CTOR), Lifevantage (LFVN), Kyverna Therapeutics (KYTX), Greenwich LifeSciences (GLSI), Nkarta (NKTX), ALT5 Sigma (ALTS), Eledon Pharmaceuticals (ELDN), and Molecular Partners (MOLN). These companies are all part of the "pharmaceutical products" industry.

PyroGenesis Canada vs. Its Competitors

PyroGenesis Canada (NASDAQ:PYRGF) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

PyroGenesis Canada has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, Black Diamond Therapeutics has a beta of 2.87, meaning that its share price is 187% more volatile than the S&P 500.

Black Diamond Therapeutics has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. Black Diamond Therapeutics' return on equity of 12.70% beat PyroGenesis Canada's return on equity.

Company Net Margins Return on Equity Return on Assets
PyroGenesis Canada-115.14% N/A -60.81%
Black Diamond Therapeutics N/A 12.70%9.58%

0.0% of PyroGenesis Canada shares are owned by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are owned by institutional investors. 47.7% of PyroGenesis Canada shares are owned by company insiders. Comparatively, 6.0% of Black Diamond Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

PyroGenesis Canada has higher earnings, but lower revenue than Black Diamond Therapeutics. PyroGenesis Canada is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PyroGenesis Canada$9.14M4.21-$21.12M-$0.03-6.84
Black Diamond Therapeutics$70M2.24-$69.68M$0.2311.96

In the previous week, Black Diamond Therapeutics had 3 more articles in the media than PyroGenesis Canada. MarketBeat recorded 3 mentions for Black Diamond Therapeutics and 0 mentions for PyroGenesis Canada. Black Diamond Therapeutics' average media sentiment score of 1.75 beat PyroGenesis Canada's score of 0.00 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
PyroGenesis Canada Neutral
Black Diamond Therapeutics Very Positive

Black Diamond Therapeutics has a consensus price target of $12.40, indicating a potential upside of 350.91%. Given Black Diamond Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Black Diamond Therapeutics is more favorable than PyroGenesis Canada.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PyroGenesis Canada
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Black Diamond Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.17

Summary

Black Diamond Therapeutics beats PyroGenesis Canada on 14 of the 17 factors compared between the two stocks.

Get PyroGenesis Canada News Delivered to You Automatically

Sign up to receive the latest news and ratings for PYRGF and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PYRGF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PYRGF vs. The Competition

MetricPyroGenesis CanadaPharmaceutical IndustryIndustrials SectorNASDAQ Exchange
Market Cap$38.46M$844.58M$7.69B$9.75B
Dividend YieldN/A4.84%4.56%4.02%
P/E Ratio-3.421.1280.6026.39
Price / Sales4.2126.5895.05159.28
Price / CashN/A19.5628.6759.42
Price / Book-20.516.724.126.59
Net Income-$21.12M-$4.49M$798.53M$265.83M
7 Day Performance-8.48%1.86%-0.18%0.18%
1 Month Performance-29.15%4.71%0.24%2.13%
1 Year Performance-65.24%22.55%27.60%21.07%

PyroGenesis Canada Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PYRGF
PyroGenesis Canada
N/A$0.21
-0.3%
N/A-64.5%$38.46M$9.14M-3.4290
BDTX
Black Diamond Therapeutics
3.3509 of 5 stars
$2.95
+1.6%
$12.40
+321.1%
-55.2%$168.26MN/A12.8590Positive News
BTMD
biote
2.4286 of 5 stars
$3.36
+1.4%
$6.00
+78.8%
-43.1%$165.67M$199.07M3.72194
CTOR
Citius Oncology
1.2439 of 5 stars
$2.10
+5.3%
$3.00
+43.2%
+30.9%$163.40MN/A0.00N/AGap Up
LFVN
Lifevantage
4.0342 of 5 stars
$13.01
+0.6%
$30.50
+134.4%
+48.7%$163.36M$200.16M18.80260News Coverage
Dividend Announcement
KYTX
Kyverna Therapeutics
2.5283 of 5 stars
$3.75
-0.8%
$15.60
+316.0%
-52.4%$162.19M$7.03M-1.0296News Coverage
Analyst Forecast
Gap Up
GLSI
Greenwich LifeSciences
1.8051 of 5 stars
$11.88
-0.5%
$42.00
+253.7%
-16.2%$161.86MN/A-8.733Positive News
NKTX
Nkarta
2.0982 of 5 stars
$2.27
+2.5%
$13.60
+500.4%
-58.0%$160.88MN/A-1.53140
ALTS
ALT5 Sigma
0.5217 of 5 stars
$7.44
+4.1%
N/A+259.9%$159.01M$12.53M0.00170High Trading Volume
ELDN
Eledon Pharmaceuticals
1.6825 of 5 stars
$2.63
+0.4%
$10.00
+280.2%
-9.8%$157.78MN/A-2.2510
MOLN
Molecular Partners
1.7585 of 5 stars
$3.80
-2.4%
$12.00
+216.2%
-41.5%$153.22M$681K-1.82180Earnings Report
Analyst Revision
Gap Down

Related Companies and Tools


This page (NASDAQ:PYRGF) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners